Skip to content

Scailyte Quarterly Update April 2021

Scailyte’s quarterly update April 2021 on the progress towards its mission to save millions of lives

Scailyte quarterly update

Scailyte quarterly update April, highlighting the three high-profile strategic partnerships, securing long-term revenue and validating our business model. Prof. Woong-Yang Park Founder and CEO of Geninus.  Here is his statement about our company – “Geninus aims to implement single-cell genome analysis techniques to facilitate personalised patient care. Scailyte’s machine learning model will add value to the single-cell gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.” Read more below:

Read our previous quarterly update here.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Meet Scailyte at BioTechX

Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.

Read more

Recent News

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

Recent News

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Recent News

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Recent News

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Recent News

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

Recent News

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News

01 /04

Meet Scailyte at BioTechX

Meet Scailyte at BioTechX at Booth #37 in Basel Congress Center from 8th to 10th November 2022.

Read more

Scailyte closes Series A funding with a CHF 6 million investment

Scailyte has successfully finished the Series A funding raising CHF 6 million from a Swiss family of

Read more

Recent News

02 /04

VACANCY: Internship in Women’s Health R&D

The internship in Women’s Health R&D will focus on our in vitro diagnostics development work in en

Read more

Nilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient

Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and t

Read more

Recent News

03 /04

Machine learning meets multi-omics for precision medicine

Bringing industry and academia together to discuss the potential impact of single-cell analytics pow

Read more

Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies

Register for Scailyte's webinar on "Understanding Resistant to CAR-T Immunotherapy to Develop Better

Read more

Recent News

04 /04

VACANCY: Technical Lead / Product Owner for a clinical diagnostic software

Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

VACANCY: Data Scientist in Biomarker Discovery

Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cel

Read more

Recent News